pharmaxis


Therapeutic products for respiratory and autoimmune diseases

> Annual General Meeting November 2007

Summary.....

Objective	The development of products for respiratory and autoimmune diseases				
Lead products	Aridol: management of asthma and COPD Bronchitol: therapeutic for cystic fibrosis and COPD				
Discovery	PXS64 - multiple sclerosis				
Listings	ASX (Nov 2003): PXS; NASDAQ (Aug 2005): PXSL				
Location	Sydney, NSW, Australia				
Facility	GMP Manufacture of lead products				
Employees	70				
Cash (30/6/07)	A\$78 million				
Shares outstanding	191m (12.7m ADS)				
Options outstanding	11.4m				
Key patents	Aridol & Bronchitol granted in USA, Australia, Asia; pending in EU, Canada and Japan				
Analyst coverage	J M P SECURITIES LIMITED CREDIT SUISSE ABN·AMRO Morgans Image: Approximate of the securities limited				

Development Pipeline



Milestones achieved FY2007.....



	1. Aridol Marketing Application Filed in Switzerland	July 2006
	2. US Aridol Trial Closes	Aug 2006
	3. Pharmaxis Appoints Aridol Distributor for Greece	Oct 2006
	4. UK Approval for Phase 3 Cystic Fibrosis Trial received	Oct 2006
	5. Aridol Distributor for Italy Appointed	Oct 2006
	6. Swedish Approval for Aridol	Oct 2006
	7. Aridol Endorsed in Global Guidelines	Nov 2006
	8. US Aridol Phase III results	Nov 2006
	9. Bronchitol Receives Fast Track Status	Nov 2006
	10. Dutch Distributor of Aridol Appointed	Dec 2006
	11. Spanish Distributor of Aridol Appointed	Jan 2007
	12. Phase III Bronchitol Trial Completes Enrolment	Feb 2007
	13. Phase II CF Study Closes Enrollment	Feb 2007
	14. Phase II Aridol COPD Results Reported	Mar 2007
	15. Phase III Cystic Fibrosis Trial Begins	Apr 2007
	16. Aridol COPD Study Enrols First Patient	May 2007
	17. Aridol Gains European Approval	Jun 2007

Milestones achieved since end FY2007......

1.	Phase III Bronchiectasis Trial Complete	July 2007
2.	Korean NDA filed for Aridol	July2007
3.	Phase III Trial Finds Pharmaxis' Bronchitol Effective	Aug 2007
4.	Placement and Share Purchase Plan	Oct 2007
5.	Korean Distributor appointed for Aridol	Oct 2007
6.	Agreement reached to expand manufacturing capacity	Nov 2007








Bronchitol






Mucus clearance:

Cystic fibrosis Chronic Obstructive Pulmonary Disease Bronchiectasis

Osmotic clearance of abnormal mucus.....


Before treatment



Lung surface dehydrated

Airway surface fluid layer impaired Lung defense and hygiene compromised

After Bronchitol administration



Lung hydrated Airway surface liquid restored Normal lung clearance

Bronchitol – cystic fibrosis

Background

- Genetic disorder affecting 75,000 worldwide (30,000 in US)
- Poorly hydrated, tenacious, thick mucus
- Current life expectancy is 37 years (US)
- Current treatments: rhDNase and tobramycin
 - Delivered by nebulizer (preparation, sterilization)
 - rhDNase (pulmozyme): US\$265mm @ ~30% penetration
 - Tobramycin: US\$233mm



- Clinical
 - Phase II proof of concept studies completed
 - Dose range finding study in progress (Canada/Argentina)



ADAM

Postural drainage is a technique for loosen ucus in the airway so that it may be coughe

Bronchitol – cystic fibrosis registration (I).....







- Phase III trial (Aus, NZ, EU):
 - 90 out of 250 subjects enrolled
 - Primary endpoint: lung function (FEV1)
 - Placebo-controlled, 6 month dosing, 400mg bd
 - First data expected end 2008
 - Market 2009
- Orphan Drug designation in the EU

Bronchitol – cystic fibrosis registration (II)......







- US Phase III trial design being finalised with FDA
- Expected to commence 1Q 2008
- Similar size, design to EU trial
- Scheduled completion 2H 2009
- Orphan drug designation EU and U.S.
- Fast track designation U.S.

Bronchitol - bronchiectasis







- Abnormal, irreversible dilation of the lower airways
- Daily mucus production, constant coughing, breathlessness, recurrent acute bronchitis with infective exacerbations : low quality of life
- In 30-50% of cases, the cause is unknown
- Normal lung clearance impaired
- Current treatments: bronchodilators, antibiotics
- No drugs proven effective to clear mucus

Number of patients seeking treatment

	EU	Australia	USA	Asia	Total
% of pt pool seen by respiratory specialists	Average 14%	9%	N/A	Average 5%	
Trend	Stable or increasing	Stable	Increasing	Stable or decreasing	
Mod/Severe	55%	70%	55%	75%	
Patients seeking treatment	210,000	18,000	110,000	250,000 ++	600,000+
Prevalence: Much higher. Bronchiectasis is often missed but has been measured as >10% of COPD patients in a US patient cohort ~ 800k					

Note: US Data comes from Datamonitor research, other data from Frost & Sullivan research

Bronchitol – bronchiectasis Phase III trial completed....



- Phase III trial (Europe, Australia, NZ)
 - 363 patient, placebo controlled, double blind, randomised 12 week treatment. 12 month Open Label Extension
 - 320mg twice a day



- Primary endpoints
 - quality of life validated Patient Reported Outcome
 - mucus clearance 24hr sputum volume
- Primary Analysis
- Quality of Life
 - Mucus Clearance
- Adverse Events

SGRQ, p<0.001 versus baseline SGRQ, p<0.05 versus placebo 128%, p<0.001 versus placebo not significant versus placebo

Bronchitol – second bronchiectasis PIII trial....

• Phase III trial (USA)




- 375 patient, placebo controlled, double blind, randomised, 26 week treatment
- 400mg twice a day
- Primary endpoints
 - quality of life validated Patient Reported Outcome
 - mucus clearance 24hr sputum volume
- Status
 - Special Protocol Assessment discussion with FDA
 - Orphan Drug designation
 - Target first patient enrolment Q1 2008
 - Target last patient enrolment Q4 2008
 - Data 2H 2009





Impact of Bronchitol on people living with bronchiectasis



Aridol[™]



A rapid and simple test for airways inflammation that facilitates diagnosis and management of asthma.



Clinical applications for Aridol

An easy to use, 'point of care' test with a high degree of sensitivity (85%) and specificity (95%) for airway inflammation

- 1. Asthma diagnosis and assessment of disease severity¹
- 2. Monitor patient's disease / managing effectiveness of treatment²
- 3. Identification of COPD patients who will respond to steroids³

NOTES: 1 = Evidence available from phase III study
2 = Proof of concept only; definitive studies ongoing
3 = Evidence available from phase II study



International Regulatory Status

- Australia
 - Launched •
- - Approved for marketing (Sweden) ۲
 - Launched
 - Approved European Union (MRP) ٠
 - 1st Launch
 - Submitted Switzerland ۲
 - Regional marketing partners appointed •
- South East Asia
 - Submitted Korea
- **USA**
 - Phase III completed. NDA to be filed 1Q08 ۲







- October 2006 September 2007

June 2006


- January 2007
- May 2007

- Europe


Aridol distribution agreements to date...

	Country	Partner	Review	National
3 15	Sweden	Nigaard	approved	\checkmark
The factor	Finland	Nigaard	approved	
155 years Dies	Germany	TBA	approved	
S AND	Ireland	Pharmaxis	approved	\checkmark
	Norway	Nigaard	approved	
	 Portugal 	TBA	approved	
	• UK	Pharmaxis	approved	
	France		approved	
	Greece	Allertec	approved	
	Italy	Italchimici	approved	
Billion and State	Holland	Romedic	approved	\checkmark
	Spain	Aldo-Union	approved	
	Denmark	Nigaard	approved	\checkmark
	 Switzerland 	Trimedal	Under review	•
- Anna	South Korea	BL&H	Under review	
				oridol ™

Worldwide development of Aridol.....



Aridol in Australia.....




Steady growth in Australia

- Price sensitivities
- Aridol challenges current practice
- □ Sales by education
- □ Australia represents
- ~1% global opportunity
- Slow EU approvals have had an impact



Research and Development activities.....









- PXS25 for immune disease
 - Reduces lung inflammation
 - Acute lung injury (ARDS), chronic lung injury (COPD)
 - Preclinical work completed
 - 1st human exposure Q1 2008
- Research group in North Ryde
 - Target protein identified
 - Potent, selective inhibitors discovered
 - Research in progress

Near term catalysts ahead.....

Milestone	4Q-07	1Q-08	2Q-08	3Q-08
Bronchitol - bronchiectasis				
Finalise US protocol with FDA			1	
Commence Phase III (US)				
File 1 st marketing appln (Aus)				
Bronchitol – cystic fibrosis				
PII dosing trial data (Can/Arg)				
Close EU P III trial recruitment				
Commence US Phase III trial				
Aridol				
File NDA (US)				
Facilities				
New facility construction begins				
PXS25/64				
Complete preclinical studies				

Financial Statements – Australian GAAP

	Year ended 30 June		
	<u>2005</u> <u>2006</u>		<u>2007</u>
Income Statements	<u>A\$'000</u>	<u>A\$'000</u>	A\$'000
Revenue from sale of goods		8	205
Cost of sales	-	(2)	(49)
Gross profit	-	6	156
Other income			
Interest	1,702	4,282	5,278
Grant income	1,219	1,299	2,152
Other	-	-	-
Expenses			
Research & development	(9,269)	(16,978)	(23,840)
Commercial	(963)	(1,946)	(3,240)
Administration	(3,134)	(4,391)	(4,666)
Total expenses	(13,366)	(23,315)	(31,746)
Net loss before tax	(10,445)	(17,728)	(24,160)
Income tax expense	-	(5)	(19)
Net loss after tax	(10,445)	(17,733)	(24,179)
Basic and diluted earnings (loss) per share - \$	(0.084)	(0.111)	(0.136)
Depreciation & amortisation	646	947	939
Fair value of employe options issued	260	1,488	1,488

Financial Statements – Australian GAAP

	As at			
	<u>30-Jun-05</u>	<u>30-Jun-06</u>	<u>30-Jun-07</u>	
Balance Sheets	<u>A\$'000</u>	<u>A\$'000</u>	<u>A\$'000</u>	
Cash and cash equivalents	33,390	97,840	76,182	
Plant & equipment	2,477	3,205	3,521	
Intangible assets	1,106	1,195	1,239	
Total assets	37,937	104,267	82,648	
Total liabilities	(2,470)	(5,379)	(6,089)	
Total shareholders' equity	35,467	98,888	76,559	
Share Data	<u>'000</u>	<u>'000</u>	<u>'000</u>	
Ordinary shares on issue	134,770	176,904	177,949	
Options on issue	10,914	9,692	9,836	

Share Capital – post 2007 equity issue

(including options)

